Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
467.3 USD | -1.35% |
|
-2.96% | +14.84% |
06-17 | Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 | MT |
06-14 | Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.84% | 121B | |
+18.31% | 112B | |
+1.95% | 22.72B | |
-18.26% | 20.82B | |
-41.55% | 16.36B | |
-14.23% | 16.19B | |
-17.89% | 16.66B | |
-0.68% | 13.17B | |
+21.87% | 11.11B | |
+111.62% | 10.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing